Newsroom

Follow Our Journey On Social Media

Latest News

BrYet US, Inc. Expands Patent Portfolio with New U.S. Patent for Targeted Drug Delivery

Nov 13, 2025

Near-term applications include combinations with kinase inhibitors (KIs) that achieve enhanced concentration at target sites and synergistic delivery of multiple KIs to the same location HOUSTON (November 13, 2025) — BrYet US, Inc. — a biotechnology innovator focused on developing curative therapies for advanced cancers — announced today that it has...

BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement

Oct 6, 2025

HOUSTON and SUNSHINE COAST, Queensland (October 6, 2025) — BrYet US, Inc. (“BrYet”), a biotechnology innovator developing a drug with the potential to be a first-in-class medicine for metastatic disease, today announced that it has received an Australian Human Research Ethics Committee (HREC) approval for its first-in-human clinical study of ML-016....

Results Published In Leading Scientific Journals

Nature Biotechnology

An injectible nanoparticle generator enhances delivery of cancer therapeutics

Science Advances

Sequential deconstruction of composite drug transport in metastatic breast cancer

Nature Reviews Cancer

Approaches from the physical sciences can contribute to the rate at which powerful new diagnostic tools and therapies can be discovered. 

Cancer Research

Targeting autocrine CCL5–CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity

Clinical Cancer Research

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery

Cell Reports

Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response 

Controlled Release

Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma

Nature Biotechnology

Principles of nanoparticle design for overcoming biological barriers to drug delivery

Advanced Science

Synergistic activation of antitumor immunity by a particulate therapeutic vaccine 

Panel: 2024 Nixon National Cancer Conference

 

BrYet CEO Dr. Mauro Ferrari joins leading cancer researchers to discuss “Precision Oncology: Tailored Care for Better Outcome”

 

Watch Now

BrYet Partners With NerPharMa

 

BrYet US, Inc. starts a Manufacturing Development Agreement with NerPharMa for its lead product candidate ML-016 against lung and liver metastases from different type of breast cancer.

 

Read More

Breast Cancer Breakthrough

 

BrYet CEO Dr. Mauro Ferrari finds that an injectable nanoparticle generator enhances delivery of cancer therapeutics.

 

Read More

Panel: Nixon National Cancer Conference

 

BrYet CEO Dr. Mauro Ferrari discusses changing the future of cancer.

 

Watch Now

Pioneering Medical Advances with Silicon

BrYet is using silicon as the basis for innovative therapeutics at effective local concentrations with the fewest possible side effects.

Read More

MedTech and the DoD

 

Learn more about how emerging medical innovations contribute to defense.

 

Read More

Join Our Email List

Learn More About BrYet

Our Team
About BrYet
Contact Us